The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers

Introduction Pancreatic cancer (PC) has an extremely poor prognosis, even with surgical resection and triplet chemotherapy treatment. Cancer immunotherapy has been recently approved for tumor-agnostic treatment with genome analysis, including in PC. However, it has limited efficacy.